Salarius (SLRX) CFO buys 20,000 shares at $0.80 in Form 4

Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum.

Rhea-AI Filing Summary

Salarius Pharmaceuticals (SLRX) reported an insider stock purchase by its Executive VP Finance and CFO, Mark J. Rosenblum. On 11/20/2025, he bought 20,000 shares of Salarius common stock at a price of $0.80 per share in an open-market transaction. After this purchase, he beneficially owns 20,177 shares of common stock, which includes 20 shares of unvested restricted stock granted on January 3, 2023. The reported post-transaction share amount reflects prior reverse stock splits that were effective on June 16, 2024 and August 17, 2025.

Insider Trade Summary

Net Buyer: 20,000 shares

Net Buy 1 txn

Insider Rosenblum Mark J

Role Exec VP Finance, CFO

Bought 20,000 shs ($16K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	20,000	$0.80	$16K

Holdings After Transaction: Common Stock — 20,177 shares (Direct)

Footnotes (2)

1. F1. Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.
2. F2. Includes 20 shares of unvested restricted stock granted on January 3, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Salarius Pharmaceuticals (SLRX) report in this Form 4?

The filing shows that Executive VP Finance and CFO Mark J. Rosenblum purchased 20,000 shares of Salarius Pharmaceuticals common stock on 11/20/2025.

At what price were the Salarius Pharmaceuticals (SLRX) shares purchased?

The 20,000 shares of Salarius Pharmaceuticals (SLRX) common stock were purchased at a price of $0.80 per share.

How many Salarius Pharmaceuticals shares does the insider own after the transaction?

Following the reported transaction, the insider beneficially owns 20,177 shares of Salarius Pharmaceuticals common stock, including 20 unvested restricted shares.

Who is the reporting person in this Salarius Pharmaceuticals (SLRX) Form 4 filing?

The reporting person is Mark J. Rosenblum, who serves as Executive Vice President Finance and Chief Financial Officer of Salarius Pharmaceuticals.

Does the share count in this Form 4 reflect any Salarius Pharmaceuticals stock splits?

Yes. The filing states that the shares beneficially owned after the transaction are adjusted to reflect reverse stock splits effective on June 16, 2024 and August 17, 2025.

Are any restricted stock awards included in the insider’s holdings of Salarius Pharmaceuticals (SLRX)?

Yes. The beneficial ownership includes 20 shares of unvested restricted stock that were granted on January 3, 2023.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/20/2025 - 04:42 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rosenblum Mark J

(Last) (First) (Middle)

C/O SALARIUS PHARMACEUTICALS, INC.

2450 HOLCOMBE BLVD., SUITE X

(Street)

HOUSTON TX 77021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Salarius Pharmaceuticals, Inc. [ SLRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec VP Finance, CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		P		20,000	A	$0.8	20,177(1)(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares beneficially owned following the transaction is adjusted to reflect the reverse stock splits effective on June 16, 2024 and August 17, 2025.

2. Includes 20 shares of unvested restricted stock granted on January 3, 2023.

Remarks:

	/s/ Mark J. Rosenblum	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.